Boryung Pharmaceutical said it has obtained the right to market Eli Lilly’s Gemzar, an anticancer treatment, in the local market.
|Eli Lilly’s anticancer treatment Gemzar|
According to IMS, a pharmaceutical market research company, Gemzar recorded local sales of 14.2 billion won ($11.6 million) in 2019. The transfer of rights came after Boryung had co-promoted the drug with Eli Lilly since 2015.The treatment has indications as a first- and second-line treatment for pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and biliary tract, as a mono- or combination therapy.
As Boryung has a high share in the domestic anticancer drug market through products such as Oxalitin and Genexol, the company expects the new sale right will strengthen its portfolio of original anticancer products as well as the overall profitability.
“With the acquisition of Gemzar’s sales rights, the company will be able to enhance its anticancer drug lineup and add a more stable source of revenue,” Boryung CEO Ahn Jae-hyun said. “We will continue to diversify our portfolio in the anticancer area and develop it into a business area that represents this company through active investment into open innovation.”
Eli Lilly Chairman David A. Ricks also said, “I hope this contract will help improve the treatment outcomes of Korean cancer patients.”
<© Korea Biomedical Review, All rights reserved.>